Wordt geladen...
Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma
Ramucirumab, a fully humanized monoclonal antibody directed against vascular endothelial growth factor receptor 2, is the first targeted agent to have demonstrated an improvement in survival, as a single agent or in combination, in a molecularly unselected population in gastro-oesophageal cancer. No...
Bewaard in:
| Gepubliceerd in: | Therap Adv Gastroenterol |
|---|---|
| Hoofdauteurs: | , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
SAGE Publications
2015
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4622287/ https://ncbi.nlm.nih.gov/pubmed/26557893 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756283X15592586 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|